- Home
- OXY vs MRNA Comparison
OXY vs MRNA Comparison
Compare OXY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXY | MRNA |
|---|---|---|
| Founded | 1920 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6B | 61.6B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OXY | MRNA |
|---|---|---|
| Price | $64.26 | $198.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 27 | 23 |
| Target Price | $69.58 | ★ $123.61 |
| AVG Volume (30 Days) | 7.8M | ★ 15.9M |
| Earning Date | 11-09-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 5.89 | N/A |
| Revenue | ★ $21,593,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $26.04 | $8.09 |
| Revenue Next Year | N/A | $16.06 |
| P/E Ratio | $10.61 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $38.80 | $22.28 |
| 52 Week High | $67.45 | $254.48 |
Technical Indicators
Market Signals| Indicator | OXY | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 50.08 |
| Support Level | $52.89 | $182.50 |
| Resistance Level | $67.45 | N/A |
| Average True Range (ATR) | 1.48 | 22.93 |
| MACD | 0.43 | -3.13 |
| Stochastic Oscillator | 93.28 | 25.66 |
Price Performance
Historical ComparisonAbout OXY Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2025, the company reported net proved reserves of 4.6 billion barrels of oil equivalent. Net production averaged 1.4 million barrels of oil equivalent per day in 2025 at a ratio of roughly 74% oil and natural gas liquids and 26% natural gas.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.